DAMORA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
DAMORA THERAPEUTICS, INC. (DMRA) had Debt Securities, Available-for-sale, Amortized Cost of $61.50 million as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-11-04
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $61.50M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $69.09M.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $74.74M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-09-30 | $61.50M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $69.09M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $74.74M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |